# Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer

> **NCT03936933** · PHASE3 · TERMINATED · sponsor: **Eurofarma Laboratorios S.A.** · enrollment: 6 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Goserelin acetate 3.6 mg Injection
- **DRUG:** ZOLADEX® 3.6mg Injection

## Key facts

- **NCT ID:** NCT03936933
- **Lead sponsor:** Eurofarma Laboratorios S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-30
- **Primary completion:** 2024-09-30
- **Final completion:** 2025-01-30
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Low recruitment rate and number of subjects is less than required after 3 years.
- **Last updated:** 2025-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03936933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03936933, "Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03936933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*